ID

19068

Descripción

Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00174863

Link

https://clinicaltrials.gov/show/NCT00174863

Palabras clave

Versiones (1)
  1. 2/12/16 2/12/16 -
Subido en

2 de diciembre de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostatic Neoplasm NCT00174863

Inglés

Eligibility Prostatic Neoplasm NCT00174863

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
prior confirmed histological diagnosis of prostatic carcinoma.
Descripción

Prostate carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0600139
rising psa while receiving hormonal therapy or after surgical castration defined as 2 sequential increases above a previous lowest reference value within the past 12 months; psa must be at least 4ng/ml at the time of study entry.
Descripción

Raised prostate specific antigen Quantity | Hormone Therapy | Male Castration | Prostate specific antigen measurement

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0178415
UMLS CUI [1,2]
C1265611
UMLS CUI [2]
C0279025
UMLS CUI [3]
C0007347
UMLS CUI [4]
C0201544
no distant metastases as evidenced by bone scan (+ or - centered x-ray or mri), and spiral thoracoabdominopelvic ct scan.
Descripción

TNM clinical staging - distant metastases Evidence of | Scan of bone | X-ray | Magnetic Resonance Imaging | Tomography, Spiral Computed

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3258247
UMLS CUI [1,2]
C0332120
UMLS CUI [2]
C0203668
UMLS CUI [3]
C0034571
UMLS CUI [4]
C0024485
UMLS CUI [5]
C0860888
effective castration throughout the study. any prior anti-androgen therapy should be stopped with documented continued elevation of psa 4 weeks after the cessation of flutamide (6 weeks for bicalutamide).
Descripción

Male Castration | Antiandrogen therapy To be stopped | Raised prostate specific antigen | Flutamide | bicalutamide

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007347
UMLS CUI [2,1]
C0279492
UMLS CUI [2,2]
C1272691
UMLS CUI [3]
C0178415
UMLS CUI [4]
C0016384
UMLS CUI [5]
C0285590
serum testosterone levels < 50ng/dl at the time of progression and throughout the study.
Descripción

Serum testosterone measurement | Disease Progression

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0428413
UMLS CUI [2]
C0242656
age > or = to 18 years.
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
extensive metabolizer by cyp2d6 genotyping.
Descripción

CYP2D6 extensive metaboliser status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3888997
karnofsky performance status > or = to 70% and life expectancy > 6 months.
Descripción

Karnofsky Performance Status | Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0206065
UMLS CUI [2]
C0023671
adequate hematological, renal and liver function.
Descripción

Hematologic function | Renal function | Liver function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
signed written informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
poor metabolizers by cyp2d6 genotyping.
Descripción

CYP2D6 poor metaboliser status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3888904
prior palliative radiotherapy or any prior chemotherapy or experimental therapy.
Descripción

Palliative radiotherapy | Chemotherapy | Therapies, Investigational

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0475092
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0949266
more than one line of any prior anticancer treatment with estrogen (estrogen or estramustine) if discontinued at least 4 weeks before study entry.
Descripción

Estrogen cancer treatment Quantity | Estramustine cancer treatment Quantity | Therapeutic procedure Discontinued

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0014939
UMLS CUI [1,2]
C0920425
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C0014921
UMLS CUI [2,2]
C0920425
UMLS CUI [2,3]
C1265611
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C1444662
concomitant administration of biphosphonate or chronic corticosteroids.
Descripción

Diphosphonates | Adrenal Cortex Hormones chronic

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0012544
UMLS CUI [2,1]
C0001617
UMLS CUI [2,2]
C0205191
presence of progressive symptoms not adequately controlled with non opioid medications
Descripción

PROGRESSIVE SYMPTOMS Control Inadequate Pharmaceutical Preparations

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0240807
UMLS CUI [1,2]
C0243148
UMLS CUI [1,3]
C0205412
UMLS CUI [1,4]
C0013227
concomitant use of medications known to be cytochrome p450 2d6 inhibitors as listed in protocol appendice
Descripción

Cytochrome P450 2D6 Inhibitors

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2962190
previous malignancies except if there has been a disease-free interval of at least 5 years and except curatively treated non-melanoma skin cancer
Descripción

Malignant Neoplasms | Interval Disease Free of | Skin carcinoma Curative treatment

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1272706
UMLS CUI [2,2]
C0012634
UMLS CUI [2,3]
C0332296
UMLS CUI [3,1]
C0699893
UMLS CUI [3,2]
C1273390
other serious illness or medical condition, which would not permit the patient to be managed according to the protocol.
Descripción

Illness Serious Preventing Therapeutic procedure | Medical condition Preventing Therapeutic procedure

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C1292733
UMLS CUI [1,4]
C0087111
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C1292733
UMLS CUI [2,3]
C0087111
Volver a la parte superior de la página

Similar models

Eligibility Prostatic Neoplasm NCT00174863

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Prostate carcinoma
Item
prior confirmed histological diagnosis of prostatic carcinoma.
boolean
C0600139 (UMLS CUI [1])
Raised prostate specific antigen Quantity | Hormone Therapy | Male Castration | Prostate specific antigen measurement
Item
rising psa while receiving hormonal therapy or after surgical castration defined as 2 sequential increases above a previous lowest reference value within the past 12 months; psa must be at least 4ng/ml at the time of study entry.
boolean
C0178415 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2])
C0007347 (UMLS CUI [3])
C0201544 (UMLS CUI [4])
TNM clinical staging - distant metastases Evidence of | Scan of bone | X-ray | Magnetic Resonance Imaging | Tomography, Spiral Computed
Item
no distant metastases as evidenced by bone scan (+ or - centered x-ray or mri), and spiral thoracoabdominopelvic ct scan.
boolean
C3258247 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0203668 (UMLS CUI [2])
C0034571 (UMLS CUI [3])
C0024485 (UMLS CUI [4])
C0860888 (UMLS CUI [5])
Male Castration | Antiandrogen therapy To be stopped | Raised prostate specific antigen | Flutamide | bicalutamide
Item
effective castration throughout the study. any prior anti-androgen therapy should be stopped with documented continued elevation of psa 4 weeks after the cessation of flutamide (6 weeks for bicalutamide).
boolean
C0007347 (UMLS CUI [1])
C0279492 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
C0178415 (UMLS CUI [3])
C0016384 (UMLS CUI [4])
C0285590 (UMLS CUI [5])
Serum testosterone measurement | Disease Progression
Item
serum testosterone levels < 50ng/dl at the time of progression and throughout the study.
boolean
C0428413 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
Age
Item
age > or = to 18 years.
boolean
C0001779 (UMLS CUI [1])
CYP2D6 extensive metaboliser status
Item
extensive metabolizer by cyp2d6 genotyping.
boolean
C3888997 (UMLS CUI [1])
Karnofsky Performance Status | Life Expectancy
Item
karnofsky performance status > or = to 70% and life expectancy > 6 months.
boolean
C0206065 (UMLS CUI [1])
C0023671 (UMLS CUI [2])
Hematologic function | Renal function | Liver function
Item
adequate hematological, renal and liver function.
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Informed Consent
Item
signed written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
CYP2D6 poor metaboliser status
Item
poor metabolizers by cyp2d6 genotyping.
boolean
C3888904 (UMLS CUI [1])
Palliative radiotherapy | Chemotherapy | Therapies, Investigational
Item
prior palliative radiotherapy or any prior chemotherapy or experimental therapy.
boolean
C0475092 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0949266 (UMLS CUI [3])
Estrogen cancer treatment Quantity | Estramustine cancer treatment Quantity | Therapeutic procedure Discontinued
Item
more than one line of any prior anticancer treatment with estrogen (estrogen or estramustine) if discontinued at least 4 weeks before study entry.
boolean
C0014939 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0014921 (UMLS CUI [2,1])
C0920425 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C1444662 (UMLS CUI [3,2])
Diphosphonates | Adrenal Cortex Hormones chronic
Item
concomitant administration of biphosphonate or chronic corticosteroids.
boolean
C0012544 (UMLS CUI [1])
C0001617 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
PROGRESSIVE SYMPTOMS Control Inadequate Pharmaceutical Preparations
Item
presence of progressive symptoms not adequately controlled with non opioid medications
boolean
C0240807 (UMLS CUI [1,1])
C0243148 (UMLS CUI [1,2])
C0205412 (UMLS CUI [1,3])
C0013227 (UMLS CUI [1,4])
Cytochrome P450 2D6 Inhibitors
Item
concomitant use of medications known to be cytochrome p450 2d6 inhibitors as listed in protocol appendice
boolean
C2962190 (UMLS CUI [1])
Malignant Neoplasms | Interval Disease Free of | Skin carcinoma Curative treatment
Item
previous malignancies except if there has been a disease-free interval of at least 5 years and except curatively treated non-melanoma skin cancer
boolean
C0006826 (UMLS CUI [1])
C1272706 (UMLS CUI [2,1])
C0012634 (UMLS CUI [2,2])
C0332296 (UMLS CUI [2,3])
C0699893 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
Illness Serious Preventing Therapeutic procedure | Medical condition Preventing Therapeutic procedure
Item
other serious illness or medical condition, which would not permit the patient to be managed according to the protocol.
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C1292733 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C1292733 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial